Epstein-Barr Virus (EBV)-Associated Diseases research hub
6 indexed studies · 3 currently recruiting
- active not recruitingPHASE2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
This study is looking at a new treatment called tabelecleucel for diseases linked to the Epstein-Barr virus (EBV). These can include certain cancers or conditions where the immune system isn't working properly. The study wants to see how well tabelecleucel works and if it's safe.
United States · Austria · Belgium - recruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
United States · Australia · United Kingdom - active not recruitingPHASE3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
This study compares a new drug combination (Lurbinectedin and Doxorubicin) against Doxorubicin alone for people with advanced leiomyosarcoma, a rare type of cancer. It aims to see if the combination can keep the cancer from growing for longer.
United States · Austria · Belgium - recruitingPHASE3
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This study looks at whether adding chemotherapy before surgery helps people with certain types of retroperitoneal sarcoma live longer without their cancer coming back. It compares surgery alone to chemotherapy followed by surgery.
United States · Australia · Canada - active not recruitingPHASE2
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This study looks at new drug combinations for certain advanced cancers. It aims to understand how these drugs affect cancer at a genetic level and in the body. It combines an immunotherapy drug with another type of cancer drug.
Canada - recruitingPHASE3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.
United States · China · Italy